AlloCure Names Robert M. Brenner, M.D. Chief Executive Officer

AlloCure in clinical
development with allogeneic mesenchymal stem cell therapy for
kidney disease

Establishing new corporate
headquarters in Burlington, MA

BURLINGTON, Mass.--(BUSINESS WIRE)--Jul 6, 2010 - AlloCure Inc.,
a biotechnology company pioneering the use of cell therapies for
the treatment of kidney diseases, today announced the appointment
of Robert M. Brenner, M.D., as President and Chief Executive
Officer. Dr. Brenner, who brings extensive clinical development and
medical affairs expertise in the field of nephrology, was
previously Senior Vice President of Medical Affairs at AMAG
Pharmaceuticals, and for nine years made leading contributions to
Amgen's global development efforts in nephrology and renal anemia.
John Wirthlin, AlloCure's prior CEO, assumes the position of Chief
Operating Officer and remains a member of the company's management
team.

“Robert Brenner's extensive medical background,
relationships with the nephrology community, and experience with
the strategic development and commercialization of important renal
therapeutics will be a major asset for AlloCure as the company
advances its novel cell therapy through the clinic and towards
commercialization,” said Lutz Giebel, Ph.D., AlloCure board
member and Managing Partner, SV Life Sciences.

“With the expansion of the company's activities in
preparation for Phase 2 clinical trials, we are pleased that John
Wirthlin will serve as COO, working closely with Rob on the
company's management team,” said Thomas Dyrberg, Senior
Partner, Novo Ventures, Novo A/S.

“AlloCure has made great strides in advancing the
promise of cell therapy for the preservation of kidney
health,” said Robert M. Brenner, M.D.” I am excited to
join the company in this dynamic period and am eager to contribute
to fully developing this therapy for the benefit of patients so
greatly in need.”

Preparing for Phase 2 Trials in Acute Kidney Injury

“Allocure has reached an important milestone in the
company's evolution, with the completion of enrollment in our Phase
1 trial in acute kidney injury,” said John Wirthlin.
“We look forward to completing this study soon and presenting
the results in an appropriate scientific forum. We are now
preparing for a Phase 2 study aimed at providing clinical
proof-of-concept for our technology.”

Robert M. Brenner, M.D. Biography

Robert M. Brenner, M.D. joins AlloCure from AMAG
Pharmaceuticals, where he was Senior Vice President of Medical
Affairs and responsible for the company's nephrology clinical
development activities. Previously, Dr. Brenner was at Amgen for
nine years where he served in a variety of nephrology leadership
roles both in clinical development and medical affairs, ultimately
holding the title of Executive Director and Renal Anemia Global
Program Area Leader. During his career, Dr. Brenner contributed to
the approval of new products, led the design of clinical trials,
and was a key liaison to the nephrology community, professional
societies and regulatory agencies.

Dr. Brenner received his B.A. from Johns Hopkins University and
his M.D. from Albert Einstein College of Medicine. He completed his
medical residency in internal medicine at Brigham and Women's
Hospital in Boston and his fellowship in nephrology at Stanford
University Medical Center.

About Acute Kidney Injury

Acute kidney injury (AKI) is a serious medical condition and is
associated with considerable morbidity, mortality and healthcare
costs. There are currently no effective treatment options to
prevent or treat AKI, other than supportive measures, including
dialysis. AlloCure's innovative cell therapy offers the promise of
improving outcomes in patients afflicted with this serious
condition.

About AlloCure

The scientists of AlloCure, founded in 2008 and previously known
as NephroGen, have made great progress in the development of the
first effective cell therapy for the treatment of kidney diseases
as well as other unmet medical needs. The AlloCure laboratory in
Hamburg, Germany, headed by Chief Scientific Officer and Professor
Axel Zander, together with Professor Claudia Lange, both prominent
stem cell biologists and bone marrow transplant experts, has
developed proprietary and highly efficient protocols for the
harvesting, expansion, and functional characterization of bone
marrow-derived human Mesenchymal Stem Cells (MSC), also termed
Multipotent Stromal Cells. These AlloCure protocols were used to
prepare the allogeneic MSCs (no matching of donor and recipient
tissues required, permitting off-the-shelf use) that were tested in
the phase I clinical trial for acute kidney injury. The design of
the trial was based on extensive pre-clinical studies conducted by
Dr. Christof Westenfelder, Chief Medical Officer, an experienced
investigator in the field of Nephrology, at AlloCure's laboratory
in Salt Lake City, Utah. This work established the protective
activity of MSCs in experimental acute kidney injury, and
identified the critical mechanisms whereby these cells both protect
and stimulate the repair and return of function of an injured
kidney or other organ. Both the Hamburg and Salt Lake City
laboratories continue to pursue important investigations in support
of the therapeutic application of these unique MSCs.

AlloCure, a privately held, venture-funded company, raised a
$14.5 million Series A financing from SV Life sciences and Novo A/S
in July 2008. The company's headquarters is located in Burlington,
MA, with other locations in Salt Lake City, UT and Hamburg,
Germany. For more information about AlloCure, please visit the
company's web site at
http://www.allocure.com.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.